Powered By Purpose
AGENDA

INTRODUCTION AND KEY RECENT EVENTS
Dave Ricks, Chairman and Chief Executive Officer

Q1 2021 FINANCIAL RESULTS
Anat Ashkenazi, Chief Financial Officer

R&D UPDATE
Dan Skovronsky, M.D., Ph.D., Chief Scientific Officer

CLOSING REMARKS
Dave Ricks, Chairman and Chief Executive Officer

QUESTION AND ANSWER SESSION

2021 Q1 EARNINGS
SAFE HARBOR PROVISION

This presentation contains forward-looking statements that are based on management’s current expectations, but actual results may differ materially due to various factors. The company’s results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform.

For additional information about the factors that affect the company’s business, please see the company’s latest Forms 10-K, 10-Q, and any 8-Ks filed with the Securities and Exchange Commission. Certain financial information in this presentation is presented on a non-GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company’s non-GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP.

The company undertakes no duty to update forward-looking statements except as required by applicable law.
Grow Revenue

- 16% revenue growth in Q1; 7% growth excluding COVID-19 antibody revenue and Q1 2020 COVID-19 related stocking benefit
- Revenue growth driven by:
  - 17% volume growth
  - Key growth products, which accounted for 52% of revenue excluding COVID-19 antibodies

Create Long-Term Value

- In-licensed RIPK1 inhibitor from Rigel Pharmaceuticals
- Agreed to sell the rights to QBREXZA, completing planned integration strategy of Dermira
- Distributed nearly $800 million via dividends in Q1

Improve Productivity

- Non-GAAP:
  - Gross margin in Q1 was 75.4% (78.0% excluding FX impact on international inventories sold)
  - Operating margin in Q1 was 27.5% (30.1% excluding FX impact on international inventories sold)

Speed Life-Changing Medicines

- Positive results from SURPASS-2, 3 & 5 trials of tirzepatide in type 2 diabetes
- Positive results from LUCENT-1 trial of mirikizumab in ulcerative colitis
- Positive results from BRAVE-AA1 & AA2 of baricitinib in alopecia areata
- Phase 3 initiatives for pirtobrutinib, formerly LOXO-305, in chronic lymphocytic leukemia and mantle cell lymphoma
- U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for bamlanivimab and etesevimab together for COVID-19
KEY EVENTS SINCE THE LAST EARNINGS CALL

REGULATORY
• The FDA extended the review period for the supplemental New Drug Application (sNDA) for baricitinib for the treatment of adults with moderate to severe atopic dermatitis which shifted The Prescription Drug User Fee Act action date by three months to early Q3; and
• Announced the outcome of the FDA Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab where the Committee voted 1 in favor and 19 against tanezumab on whether the proposed risk evaluation and mitigation strategy will ensure its benefits outweigh its risks.

CLINICAL
• Announced positive top-line results from three Phase 3 clinical trials of tirzepatide in adults with type 2 diabetes in terms of A1C and body weight reductions from baseline. The three trials compared tirzepatide to titrated insulin degludec, to placebo, both as an add-on to titrated insulin glargine, and to injectable semaglutide 1 mg;
• Presented positive Phase 2 results for donanemab that expanded on previously reported top-Line data that found donanemab met its primary endpoint and showed significant slowing of decline compared to placebo on the integrated Alzheimer’s Disease Rating Scale (iADRS), a composite measure of cognition and daily function, in patients with early symptomatic Alzheimer’s disease;
• Announced the expansion of the Phase 3 TRAILBLAZER-ALZ 2 study for donanemab in early Alzheimer’s disease and the plan to initiate a new Phase 3 study, TRAILBLAZER-ALZ 3, for donanemab in asymptomatic Alzheimer’s disease;

CLINICAL (CONT.)
• Announced positive top-line results for mirikizumab in a Phase 3 induction study for the treatment of patients with moderate to severe ulcerative colitis which met the primary and all key secondary endpoints evaluating the efficacy and safety of mirikizumab;
• Announced the development program for mirikizumab will focus only on ulcerative colitis and Crohn’s disease with no plan to submit mirikizumab for regulatory approval in psoriasis in any geography; and
• Announced positive top-line results from two Phase 3 studies for baricitinib in adults with severe alopecia areata, where baricitinib met the primary efficacy endpoint at week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo.

BUSINESS DEVELOPMENT
• Announced a global exclusive license agreement and strategic collaboration with Rigel Pharmaceuticals to co-develop and commercialize Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications, and Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS);
• Announced a collaboration and licensing agreement with Welldoc to integrate Welldoc’s software into Lilly’s connected insulin solutions, currently in development. Lilly will commercialize the pen platform, which will include the new app and Lilly’s connected insulin pen solutions; and
• Announced a research collaboration and license agreement with Biolologic Design that will leverage Biolologic’s AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes.
KEY EVENTS SINCE THE LAST EARNINGS CALL

COVID-19 & OTHER

- The FDA granted EUA for investigational bamlanivimab and etesevimab together for the treatment of mild to moderate COVID-19 patients who are at high risk for progressing to severe COVID-19 and/or hospitalization. As part of the previously reported collaboration with the company, Amgen began manufacturing etesevimab;
- Announced a purchase agreement with the U.S. government to purchase up to 1.2 million doses of bamlanivimab and etesevimab together by November 2021, with 100k doses ordered for shipment by March 31, 2021 at a value of $210M;
- Modified the purchase agreement for COVID-19 antibodies with the U.S. government to focus on supply of bamlanivimab and etesevimab together to enable the supply of etesevimab alone to complement doses of bamlanivimab the U.S. government already purchased. This terminated the purchase agreement for bamlanivimab alone and cancelled the remaining 350,856 doses that were scheduled to be delivered by the end of March 2021;
- Requested revocation of EUA for bamlanivimab alone to complete the transition to only supply bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S. The FDA subsequently revoked the EUA for bamlanivimab alone;
- The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive scientific opinion for bamlanivimab alone and bamlanivimab and etesevimab together for the treatment of COVID-19 patients who are at high risk for progressing to severe COVID-19;
- Shared data from a new Phase 3 cohort of BLAZE-1 which showed treatment with COVID-19 antibodies bamlanivimab and etesevimab together significantly reduced risk of COVID-19 related hospitalizations and death by 87% in high-risk patients;

COVID-19 & OTHER (CONT.)

- Announced positive top-line data from the expanded Phase 2 trial which showed that investigational bamlanivimab co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 percent relative reduction in persistently high viral load at day 7 compared to placebo;
- Announced top-line data for a Phase 3 study evaluating baricitinib plus standard of care (SoC) versus placebo plus SoC, which did not meet statistical significance on the primary endpoint but showed that treatment with baricitinib in addition to SoC resulted in a significant reduction in death from any cause by 38 percent by day 28;
- Announced several recent and upcoming executive leadership transitions, including the appointment of Anat Ashkenazi as senior vice president and chief financial officer, the appointment of Edgardo Hernandez as senior vice president and president of manufacturing operations, the appointment of Diogo Rau as senior vice president and chief information and digital officer, and the appointment of Alonzo Weems as senior vice president, enterprise risk management and chief ethics and compliance officer;
- The Board of Directors elected Kimberly H. Johnson as a new member, serving on both the Compensation and Ethics and Compliance Committees; and
- Announced plans to host a webcast to provide an overview of the company’s sustainability efforts in the areas of Environmental, Social, and Governance for the investment community, media, and the general public on May 4, 2021.
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION; CERTAIN LINE ITEMS (UNAUDITED)

Millions; except per share data

<table>
<thead>
<tr>
<th></th>
<th>GAAP Reported</th>
<th>Adjustments</th>
<th>Non-GAAP Adjusted</th>
<th>Non-GAAP Adjusted Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL REVENUE</td>
<td>$6,806</td>
<td>-</td>
<td>$6,806</td>
<td>16%</td>
</tr>
<tr>
<td>GROSS MARGIN</td>
<td>72.4%</td>
<td>3.0%</td>
<td>75.4%</td>
<td>(4.9pp)</td>
</tr>
<tr>
<td>TOTAL OPERATING EXPENSE</td>
<td>3,772</td>
<td>(511)</td>
<td>3,261</td>
<td>11%</td>
</tr>
<tr>
<td>OPERATING INCOME</td>
<td>1,155</td>
<td>718</td>
<td>1,873</td>
<td>6%</td>
</tr>
<tr>
<td>OPERATING MARGIN</td>
<td>17.0%</td>
<td>10.5%</td>
<td>27.5%</td>
<td>(2.5pp)</td>
</tr>
<tr>
<td>OTHER INCOME (EXPENSE)</td>
<td>321</td>
<td>(287)</td>
<td>35</td>
<td>NM</td>
</tr>
<tr>
<td>EFFECTIVE TAX RATE</td>
<td>8.2%</td>
<td>2.6%</td>
<td>10.8%</td>
<td>(2.1pp)</td>
</tr>
<tr>
<td>NET INCOME</td>
<td>$1,355</td>
<td>347</td>
<td>$1,702</td>
<td>16%</td>
</tr>
<tr>
<td>EPS</td>
<td>$1.49</td>
<td>$0.38</td>
<td>$1.87</td>
<td>16%</td>
</tr>
</tbody>
</table>

Note: Numbers may not add due to rounding; see slide 26 for a complete list of significant adjustments.
# PRICE RATE VOLUME EFFECT ON REVENUE

**Millions**

<table>
<thead>
<tr>
<th></th>
<th>Amount</th>
<th>Price</th>
<th>FX Rate</th>
<th>Volume</th>
<th>Total</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>U.S.</strong></td>
<td>$3,941</td>
<td>(6)%</td>
<td>-%</td>
<td>24%</td>
<td>18%</td>
<td>18%</td>
</tr>
<tr>
<td><strong>EUROPE</strong></td>
<td>1,321</td>
<td>(0)%</td>
<td>10%</td>
<td>15%</td>
<td>24%</td>
<td>15%</td>
</tr>
<tr>
<td><strong>JAPAN</strong></td>
<td>572</td>
<td>(2)%</td>
<td>4%</td>
<td>(6)%</td>
<td>(3)%</td>
<td>(8)%</td>
</tr>
<tr>
<td><strong>CHINA</strong></td>
<td>362</td>
<td>(6)%</td>
<td>9%</td>
<td>32%</td>
<td>35%</td>
<td>26%</td>
</tr>
<tr>
<td><strong>REST OF WORLD</strong></td>
<td>609</td>
<td>(2)%</td>
<td>1%</td>
<td>2%</td>
<td>(0)%</td>
<td>(1)%</td>
</tr>
<tr>
<td><strong>TOTAL REVENUE</strong></td>
<td>$6,806</td>
<td>(4)%</td>
<td>3%</td>
<td>17%</td>
<td>16%</td>
<td>13%</td>
</tr>
</tbody>
</table>

**Note:** Numbers may not add due to rounding

**CER = price change + volume change**
## Contribution to 17% Q1 WW Volume Growth

<table>
<thead>
<tr>
<th>Product</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 Antibodies</td>
<td>13.8%</td>
</tr>
<tr>
<td>Key Products*</td>
<td>9.5%</td>
</tr>
<tr>
<td>Alimta®</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Tradjenta®</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Forteo®</td>
<td>-1.4%</td>
</tr>
<tr>
<td>LOE**</td>
<td>-1.9%</td>
</tr>
<tr>
<td>All Other</td>
<td>-2.3%</td>
</tr>
</tbody>
</table>

Numbers do not add due to rounding

Jardiance®, Basaglar® and Tradjenta are part of the Boehringer Ingelheim (BI) and Lilly Alliance and BI holds the marketing authorization for Jardiance

* includes Cyramza®, Emgality®, Jardiance, Olumiant®, Retevmo™, Taltz®, Trulicity®, Tyyvy®, and Verzenio®

** LOE: loss of exclusivity; includes Axiron®, Cialis®, Cymbalta®, Effient®, Evista®, Strattera®, and Zyprexa®

Note: COVID-19 antibody sales were made pursuant to Emergency Use Authorization

2021 Q1 EARNINGS
UPDATE ON KEY GROWTH PRODUCTS

**RETEVMO**
- U.S. approval May 2020 in advanced RET-driven lung and thyroid cancers

**TYVYT**
- Added to China’s National Drug Reimbursement List in 2020

**EMGALITY**
- U.S. NBRx SOM 39% at the end of Q1 2021
- U.S. TRx 37% SOM at end of Q1 2021

**VERZENIO**
- U.S. NBRx SOM nearly 28% at end of Q1 2021
- U.S. TRx grew 30%* vs. Q1 2020, outpacing the market

**OLUMIANT**
- OUS sales grew 32% vs. Q1 2020

**TALTZ**
- IL-17 dermatology leader in U.S. TRx SOM 19%
- U.S. TRx grew nearly 21% vs. Q1 2020

**JARDIANCE**
- Market leader in U.S. TRx SOM 60% and NTS SOM 63%
- U.S. SGLT2 class grew nearly 18% vs. Q1 2020

**CYRAMZA**
- WW sales growth +1% vs. Q1 2020

**TRULICITY**
- Market leader in U.S. TRx SOM 48% (injectable GLP-1)
- U.S. injectable GLP-1 class grew 16% vs. Q1 2020

---

Note: Jardiance is sold by Boehringer Ingelheim; Lilly records as revenue its share of Jardiance gross margin; Jardiance, Basaglar and Tradjenta are part of the Boehringer Ingelheim and Lilly Alliance.

*Verzenio TRx growth normalized for additional prescription data capture in the base period.

2021 Q1 EARNINGS
Q1 2021 Capital Allocation

- **R&D***: $1.5
- **Capital Investments**: $0.3
- **Business Development**: $1.0
- **Dividend**: $0.8
- **Share Repurchase**: $0.0

*After-tax (non-GAAP)*

**Includes equity investments and cash inflows from sale of product rights**
## 2021 GUIDANCE

<table>
<thead>
<tr>
<th>Category</th>
<th>Prior</th>
<th>Updated</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOTAL REVENUE</strong></td>
<td>$26.5 – $28.0 billion</td>
<td>$26.6 – $27.6 billion</td>
<td>Reflects $100M increase to the core business for FX benefits; COVID-19 antibodies revenue range narrowed to $1-$1.5B</td>
</tr>
<tr>
<td><strong>GROSS MARGIN % (GAAP)</strong></td>
<td>approx. 77%</td>
<td>Unchanged</td>
<td></td>
</tr>
<tr>
<td><strong>GROSS MARGIN % (NON-GAAP)</strong></td>
<td>approx. 79%</td>
<td>Unchanged</td>
<td></td>
</tr>
<tr>
<td><strong>MKTG, SELLING &amp; ADMIN.</strong></td>
<td>$6.2 – $6.4 billion</td>
<td>Unchanged</td>
<td></td>
</tr>
<tr>
<td><strong>RESEARCH &amp; DEVELOPMENT</strong></td>
<td>$6.5 – $6.7 billion</td>
<td>$6.9 – $7.1 billion</td>
<td>Reflects an increase for investments in donanemab; COVID-19 antibodies range increased to $400-$500M</td>
</tr>
<tr>
<td><strong>OTHER INCOME/(EXPENSE) (GAAP)</strong></td>
<td>$(300) – $(200) million</td>
<td>$150 – $250 million</td>
<td>Reflects Q1 2021 equity investment gains and Alimta patent settlement in Europe</td>
</tr>
<tr>
<td><strong>OTHER INCOME/(EXPENSE) (NON-GAAP)</strong></td>
<td>$(300) – $(200) million</td>
<td>$(200) – $(100) million</td>
<td>Reflects Alimta patent settlement in Europe</td>
</tr>
<tr>
<td><strong>TAX RATE</strong></td>
<td>approx. 15%</td>
<td>approx. 13%</td>
<td>Reflects higher discrete tax items in Q1 2021 and a lower base rate</td>
</tr>
<tr>
<td><strong>EARNINGS PER SHARE (GAAP)</strong></td>
<td>$7.10 – $7.75</td>
<td>$7.03 – $7.23</td>
<td>Reflects increases to acquired IPR&amp;D, other specified items and equity investment gains</td>
</tr>
<tr>
<td><strong>EARNINGS PER SHARE (NON-GAAP)</strong></td>
<td>$7.75 – $8.40</td>
<td>$7.80 – $8.00</td>
<td>Reflects adjustments to revenue, research &amp; development expense, other income/(expense) and tax rate</td>
</tr>
<tr>
<td><strong>OPERATING INCOME % (GAAP)</strong></td>
<td>approx. 30%</td>
<td>approx. 26%</td>
<td>Reflects increases to acquired IPR&amp;D and other specified items</td>
</tr>
<tr>
<td><strong>OPERATING INCOME % (NON-GAAP)</strong></td>
<td>approx. 32%</td>
<td>approx. 31%</td>
<td>Reflects adjustments to revenue and research &amp; development expense</td>
</tr>
</tbody>
</table>

Assumes GAAP and non-GAAP shares outstanding 909 million

Not for promotional use

Updated FX assumptions of 1.17 [Euro], 110 [Yen] and 6.59 [Renminbi]
SURPASS HIGHLIGHTS: SIGNIFICANT HBA1C REDUCTION
TIRZEPATIDE SIGNIFICANTLY REDUCED HBA1C ACROSS DOSES DEMONSTRATING SUPERIORITY VS. ALL COMPARATORS

SURPASS-1
(40 Weeks)
Baseline HbA1c: 7.9%
N = 478

SURPASS-2
(40 Weeks)
Baseline HbA1c: 8.3%
N = 1,879

SURPASS-3
(52 Weeks)
Baseline HbA1c: 8.2%
N = 1,444

SURPASS-5
(40 Weeks)
Baseline HbA1c: 8.3%
N = 475

*denotes statistical significance to comparator; TZP = tirzepatide; OAM = Oral Antidiabetic Medication; SGLT-2i = sodium-glucose co-transporter-2 inhibitor
Results presented using the efficacy estimand, which represents efficacy prior to discontinuation of study drug or initiating rescue therapy for persistent severe hyperglycemia

Not for promotional use

2021 Q1 EARNINGS
SURPASS HIGHLIGHTS: HBA1C < 5.7%
BETWEEN 26% AND 62% OF TIRZEPATIDE-TREATED PATIENTS ACHIEVED A NORMAL HBA1C LEVEL (<5.7%)

SURPASS-1
(40 Weeks)

SURPASS-2
(40 Weeks)

SURPASS-3
(52 Weeks)

SURPASS-5
(40 Weeks)

No background OAMs

Background Metformin

Background Metformin, or Metformin + SGLT-2i

Background Insulin Glargine, with or without Metformin

* denotes statistical significance to comparator; †Not controlled for type I error; TZP = tirzepatide; OAM = Oral Antidiabetic Medication; SGLT-2i = sodium-glucose co-transporter-2 inhibitor
Results presented using the efficacy estimand, which represents efficacy prior to discontinuation of study drug or initiating rescue therapy for persistent severe hyperglycemia

Not for promotional use

2021 Q1 EARNINGS
SURPASS HIGHLIGHTS: SIGNIFICANT WEIGHT REDUCTION
AT THE HIGHEST DOSE OF TIRZEPATIDE, PARTICIPANTS LOST UP TO 12.9 KG (28.4 LBS)

SURPASS-1
(40 Weeks)
Baseline Weight: 85.9 kg

SURPASS-2
(40 Weeks)
Baseline Weight: 93.7 kg

SURPASS-3
(52 Weeks)
Baseline Weight: 94.3 kg

SURPASS-5
(40 Weeks)
Baseline Weight: 95.2 kg

*denotes statistical significance to comparator; TZP = tirzepatide; OAM = Oral Antidiabetic Medication; SGLT-2i = sodium-glucose co-transporter-2 inhibitor
Results presented using the efficacy end point, which represents efficacy prior to discontinuation of study drug or initiating rescue therapy for persistent severe hyperglycemia

2021 Q1 EARNINGS

Not for promotional use
SURPASS HIGHLIGHTS: TOLERABILITY
TIRZEPATIDE SAFETY PROFILE WAS SIMILAR TO WELL ESTABLISHED GLP-1 RECEPTOR AGONIST CLASS

SURPASS-1
(40 Weeks)

SURPASS-2
(40 Weeks)

SURPASS-3
(52 Weeks)

SURPASS-5
(40 Weeks)

DISCONTINUATION RATES DUE TO ADVERSE EVENTS WERE BETWEEN 3% AND 11% ACROSS DOSES

TZP = tirzepatide; OAM = Oral Antidiabetic Medication; SGLT-2i = sodium-glucose co-transporter-2 inhibitor

Not for promotional use

2021 Q1 EARNINGS
# Lilly Select NME and Nilex Pipeline

**April 23, 2021**

## Not for promotional use

### phases

**Phase 1**
- Ly-CoV544 MAB COVID-19
- GIP/GLP agonist PEPTIDE Diabetics / NASH
- GIPR agonist LA Diabetes
- IDHT INHIBITOR Cancer
- GGG TRI-Agonist Diabetes
- O-GlcNAcase INH Alzheimer’s
- BTLA MAB AGONIST Immunology
- CD73 INHIBITOR Cancer

**Phase 2**
- RELAXIN-LA Heart Failure
- Ly-CoV544 MAB COVID-19
- GIP/GLP COAGONIST PEPTIDE II Diabetes
- KHK INHIBITOR II Diabetes / NASH
- GIPR AGONIST LA Diabetes
- IDHT INHIBITOR Cancer
- GGG TRI-Agonist Diabetes
- O-GlcNAcase INH Alzheimer’s
- BTLA MAB AGONIST Immunology
- CD73 INHIBITOR Cancer

**Phase 3**
- P2X7 INHIBITOR Pain
- GLP-1R NPA Diabetes
- N3PG Aβ MAB Alzheimer’s
- TRP1 ANTAGONIST Pain
- RELAXIN-LA Heart Failure
- NOT DISCLOSED Diabetes
- RPK1 INHIBITOR Immunology
- P2X7 INHIBITOR Pain
- ANGPT3 VNA CVD
- LY-CoV544 MAB COVID-19
- GIP/GLP COAGONIST PEPTIDE II Diabetes
- KHK INHIBITOR II Diabetes / NASH
- GIPR AGONIST LA Diabetes
- IDHT INHIBITOR Cancer
- GGG TRI-Agonist Diabetes
- O-GlcNAcase INH Alzheimer’s
- BTLA MAB AGONIST Immunology
- CD73 INHIBITOR Cancer

### legend

- NME
- NILEX
- Commercial Collaboration
- Emergency Use Authorization has been granted in the US and other countries

### Movements since January 26, 2021

- Movement or Milestone Achieved
- Removal

### Notable Events

- Bamlanivimab & Etesevimab for COVID-19
- Baricitinib for RA
- Seltenzumab for Psoriasis
- Donanemab for Early Alzheimer’s

### Approved Products

- Ly-CoV544 MAB for COVID-19
- Bamlanivimab & Etesevimab for COVID-19

### Commercial Collaboration

- Abemaciclib
- Empagliflozin
- Seltenzumab
- Donanemab

### Phase 1

- Ly-CoV544 MAB COVID-19
- GIP/GLP COAGONIST PEPTIDE II Diabetes
- KHK INHIBITOR II Diabetes / NASH
- GIPR AGONIST LA Diabetes
- IDHT INHIBITOR Cancer
- GGG TRI-Agonist Diabetes
- O-GlcNAcase INH Alzheimer’s
- BTLA MAB AGONIST Immunology
- CD73 INHIBITOR Cancer

### Phase 2

- RELAXIN-LA Heart Failure
- Ly-CoV544 MAB COVID-19
- GIP/GLP COAGONIST PEPTIDE II Diabetes
- KHK INHIBITOR II Diabetes / NASH
- GIPR AGONIST LA Diabetes
- IDHT INHIBITOR Cancer
- GGG TRI-Agonist Diabetes
- O-GlcNAcase INH Alzheimer’s
- BTLA MAB AGONIST Immunology
- CD73 INHIBITOR Cancer

### Phase 3

- P2X7 INHIBITOR Pain
- GLP-1R NPA Diabetes
- N3PG Aβ MAB Alzheimer’s
- TRP1 ANTAGONIST Pain
- RELAXIN-LA Heart Failure
- NOT DISCLOSED Diabetes
- RPK1 INHIBITOR Immunology
- P2X7 INHIBITOR Pain
- ANGPT3 VNA CVD
- ANGPTL3/8 MAB CVD
- IL-2 CONJUGATE Ulcerative Colitis
- BTLA MAB AGONIST Immunology
- AUR A KINASE INHIBITOR Cancer
- OXYNTOMODULIN Diabetes
- CD73 INHIBITOR Cancer

### Notable Events

- Bamlanivimab & Etesevimab for COVID-19
- Baricitinib for RA
- Seltenzumab for Psoriasis
- Donanemab for Early Alzheimer’s

### Approved Products

- Ly-CoV544 MAB for COVID-19
- Bamlanivimab & Etesevimab for COVID-19

### Commercial Collaboration

- Abemaciclib
- Empagliflozin
- Seltenzumab
- Donanemab

### Movements since January 26, 2021

- Movement or Milestone Achieved
- Removal

## Q1 Earnings 2021

Not for promotional use
Phase 3 Initiations
- Abemaciclib for HR+, HER2+ early breast cancer
- Pirtobrutinib (LOXO-305) for MCL monotherapy
- Pirtobrutinib (LOXO-305) for CLL monotherapy
- Pirtobrutinib (LOXO-305) for CLL combination therapy
- Pirtobrutinib (LOXO-305) for CLL first-line
- Tirzepatide for obesity [3 additional studies]
- Tirzepatide for HFpEF
- Donanemab for asymptomatic Alzheimer’s disease

Phase 3 & Other Key Data Disclosures
- Baricitinib for alopecia areata
- Baricitinib for systemic lupus erythematosus
- Donanemab for early Alzheimer’s disease
- Empagliflozin for HFpEF
- Lebrikizumab for atopic dermatitis
- Mirikizumab for ulcerative colitis (induction data)
- Mirikizumab for ulcerative colitis (maintenance data)
- Tirzepatide for type 2 diabetes [SURPASS-2]
- Tirzepatide for type 2 diabetes [SURPASS-3]
- Tirzepatide for type 2 diabetes [SURPASS-4]
- Tirzepatide for type 2 diabetes [SURPASS-5]
- Zagotenemab for early Alzheimer’s disease

Medical Meeting Presentations
- Donanemab for early Alzheimer’s disease
- Oral SERD for metastatic breast cancer
- Tirzepatide for type 2 diabetes

Regulatory Submissions
- Abemaciclib for high-risk HR+, HER2- early breast cancer [J]
- Baricitinib for alopecia areata
- Bamlanivimab + Etesevimab for COVID-19 [EU/US]
- Sintilimab for NSCLC [US]
- Tirzepatide for type 2 diabetes [US/EU/J]

Regulatory Actions
- Abemaciclib for high-risk HR+, HER2- early breast cancer (US/EU/J)
- Baricitinib for atopic dermatitis (US/J)
- Empagliflozin for HFpEF (US/EU/J)
- Selpercatinib for NSCLC and thyroid cancers [EU/J]
- Tanezumab for osteoarthritis pain (US)
- Bamlanivimab + Etesevimab EUA for COVID-19
- Baricitinib for COVID-19 (J)

1 in collaboration with Boehringer Ingelheim
2 in collaboration with Pfizer
3 Japan approval occurred in Q4 2020
Q1 2021 PERFORMANCE SUMMARY

- **Volume-driven revenue growth** of 17%, with key growth products comprising the majority of revenue excluding COVID-19 antibodies

- Operating margin of 30.1%, excluding FX impact on international inventories sold with **continued expansion expected** throughout the year

- Progress on our **innovation-based strategy**, including positive data readouts for tirzepatide, mirikizumab and baricitinib, Phase 3 initiations for pirtobrutinib and EUA authorization for bamlanivimab and etesevimab together for COVID-19

- Deployed nearly $800 million to shareholders via the dividend
SUPPLEMENTARY SLIDES
Millions; except per share data

<table>
<thead>
<tr>
<th></th>
<th>Q1 2021</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL REVENUE</td>
<td>$6,806</td>
<td>16%</td>
</tr>
<tr>
<td>GROSS MARGIN</td>
<td>72.4%</td>
<td>(6.9pp)</td>
</tr>
<tr>
<td>TOTAL OPERATING EXPENSE*</td>
<td>3,772</td>
<td>24%</td>
</tr>
<tr>
<td>OPERATING INCOME</td>
<td>1,155</td>
<td>(27%)</td>
</tr>
<tr>
<td>OPERATING MARGIN</td>
<td>17.0%</td>
<td>(10.2pp)</td>
</tr>
<tr>
<td>OTHER INCOME (EXPENSE)</td>
<td>321</td>
<td>NM</td>
</tr>
<tr>
<td>EFFECTIVE TAX RATE</td>
<td>8.2%</td>
<td>(5.1pp)</td>
</tr>
<tr>
<td>NET INCOME - CONTINUING OPERATIONS</td>
<td>$1,355</td>
<td>(7%)</td>
</tr>
<tr>
<td>EARNINGS PER SHARE</td>
<td>$1.49</td>
<td>(7%)</td>
</tr>
</tbody>
</table>

*Includes research and development expense, marketing, selling and administrative expense, acquired in-process research and development charges, and asset impairment, restructuring and other special charges.
NM – not meaningful
NON-GAAP GROSS MARGIN % OF REVENUE

MOVING ANNUAL TOTAL

<table>
<thead>
<tr>
<th></th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
<th>Q1</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>80.2%</td>
<td>81.0%</td>
<td>79.6%</td>
<td>79.9%</td>
<td>80.3%</td>
<td>79.6%</td>
<td>79.1%</td>
<td>78.6%</td>
<td>75.4%</td>
</tr>
<tr>
<td>2020</td>
<td>80.2%</td>
<td>80.2%</td>
<td>78.9%</td>
<td>79.6%</td>
<td>80.6%</td>
<td>79.1%</td>
<td>79.9%</td>
<td>79.1%</td>
<td>78.0%</td>
</tr>
</tbody>
</table>

Individual quarter GM % of Revenue:
- with FX effect on int’l inv sold
- w/o FX effect on int’l inv sold

Note: The lines in the graph are moving annual totals (i.e. trailing 4 quarters) while the two rows of numbers are from specific quarters.

Not for promotional use

2021 Q1 EARNINGS
NON-GAAP OPERATING MARGIN % OF REVENUE

MOVING ANNUAL TOTAL

Without FX effect on int’l inventories sold
With FX effect on int’l inventories sold

<table>
<thead>
<tr>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
<th>Q1</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Individual quarter Op. Margin % of Revenue:
- with FX effect on int’l inv sold
  - 26.2%
  - 27.9%
  - 28.6%
  - 26.3%
  - 30.1%
  - 28.0%
  - 26.2%
  - 33.0%
  - 27.5%
- w/o FX effect on int’l inv sold
  - 26.2%
  - 27.2%
  - 27.9%
  - 25.9%
  - 30.4%
  - 27.5%
  - 27.0%
  - 33.5%
  - 30.1%

Note: The lines in the graph are moving annual totals (i.e. trailing 4 quarters) while the two rows of numbers are from specific quarters.
## EFFECT OF FX ON 2021 RESULTS

### Year-on-Year Growth

<table>
<thead>
<tr>
<th></th>
<th>REPORTED</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>With FX</td>
<td>w/o FX</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL REVENUE</td>
<td>16%</td>
<td>13%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COST OF SALES</td>
<td>55%</td>
<td>39%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GROSS MARGIN</td>
<td>6%</td>
<td>7%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPERATING EXPENSE</td>
<td>24%</td>
<td>22%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPERATING INCOME</td>
<td>(27%)</td>
<td>(23%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EARNINGS PER SHARE</td>
<td>(7%)</td>
<td>(2%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### NON-GAAP

<table>
<thead>
<tr>
<th></th>
<th>With FX</th>
<th>w/o FX</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL REVENUE</td>
<td>16%</td>
<td>13%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COST OF SALES</td>
<td>45%</td>
<td>29%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GROSS MARGIN</td>
<td>9%</td>
<td>10%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPERATING EXPENSE</td>
<td>11%</td>
<td>10%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OPERATING INCOME</td>
<td>6%</td>
<td>10%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EARNINGS PER SHARE</td>
<td>16%</td>
<td>20%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# EPS RECONCILIATION

<table>
<thead>
<tr>
<th></th>
<th>Q1 2021</th>
<th>Q1 2020</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS (REPORTED)</td>
<td>$1.49</td>
<td>$1.60</td>
<td>(7%)</td>
</tr>
<tr>
<td>ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT</td>
<td>0.26</td>
<td>0.05</td>
<td></td>
</tr>
<tr>
<td>OTHER SPECIFIED ITEMS</td>
<td>0.26</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>AMORTIZATION OF INTANGIBLE ASSETS</td>
<td>0.11</td>
<td>0.05</td>
<td></td>
</tr>
<tr>
<td>EQUITY INVESTMENT GAINS/LOSSES</td>
<td>(0.25)</td>
<td>(0.14)</td>
<td></td>
</tr>
<tr>
<td>EPS (NON-GAAP)</td>
<td>$1.87</td>
<td>$1.61</td>
<td>16%</td>
</tr>
</tbody>
</table>

Note: Numbers may not add due to rounding; see slide 26 for more details on these significant adjustments.
Q1 2021 INCOME STATEMENT NOTES

Q1 2021 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- amortization of intangible assets primarily associated with costs of marketed products acquired or licensed from third parties totaling $125.7 million (pretax), or $0.11 per share (after-tax);
- acquired in-process R&D charges totaling $299.3 million (pretax), or $0.26 per share (after-tax), related to business development transactions with Rigel Pharmaceuticals, Inc., Precision BioSciences, Inc., Merus N.V., and Asahi Kasei Pharma Corporation;
- asset impairment, restructuring and other special charges, primarily an intangible asset impairment resulting from the decision to sell the rights to QBREXZA, charges resulting from excess inventory due in part to the discontinuation of bamlanivimab for use on its own, as well as acquisition and integration costs recognized as part of the closing of the acquisition of Prevail Therapeutics Inc., totaling $293.1 million (pretax), or $0.26 per share (after-tax); and
- gains and losses on investments in equity securities totaling $286.5 million (pretax), or ($0.25) per share (after-tax).

Q1 2020 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- amortization of intangible assets primarily associated with costs of marketed products acquired or licensed from third parties totaling $54.4 million (pretax), or $0.05 per share (after-tax);
- acquired in-process R&D charges totaling $52.3 million (pretax), or $0.05 per share (after-tax), related to business development activity other than a business combination, related to Sitryx;
- asset impairment, restructuring and other special charges, primarily acquisition and integration costs associated with the acquisition of Dermira, Inc., totaling $64.1 million (pretax), or $0.06 per share (after-tax); and
- gains and losses on investments in equity securities totaling $161.7 million (pretax), or ($0.14) per share (after-tax).
## COMPARATIVE EPS SUMMARY 2020/2021

<table>
<thead>
<tr>
<th></th>
<th>1Q20</th>
<th>2Q20</th>
<th>3Q20</th>
<th>4Q20</th>
<th>2020</th>
<th>1Q21</th>
<th>2Q21</th>
<th>3Q21</th>
<th>4Q21</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported</td>
<td>1.60</td>
<td>1.55</td>
<td>1.33</td>
<td>2.32</td>
<td>6.79</td>
<td>1.49</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-GAAP</td>
<td>1.61</td>
<td>1.45</td>
<td>1.41</td>
<td>2.31</td>
<td>6.78</td>
<td>1.87</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Numbers may not add due to rounding.

For a complete reconciliation to reported earnings, see slide 26 and our earnings press release dated April 27, 2021.
Q1 2021 TRULICITY SALES INCREASED 18%

U.S. sales increased 20%
International sales increased 12%

Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 26, 2021; RA = rolling average
Note: TRx data is representative of the injectable GLP-1 market
Millions

U.S. sales decreased 24%
International sales increased 32%

Source: IQVIA NPA TRx 3MMA, weekly data March 26, 2021; RA = rolling average
Note: TRx data is representative of the full molecule market

Not for promotional use
Q1 2021 JARDIANCE SALES INCREASED 17%

Millions

U.S. sales increased 5%
International sales increased 31%

Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 26, 2021; RA = rolling average
Note: Jardiance is part of the Boehringer Ingelheim and Lilly Alliance

2021 Q1 EARNINGS

Not for promotional use
Q1 2021 VERZENIO SALES INCREASED 43%

Millions

U.S. sales increased 34%
International sales increased 64%

U.S. TRx SOM and Market Volume

Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 26, 2021; RA = rolling average
Note: Q2 2020 IQVIA data was impacted by an addition of data for Verzenio

2021 Q1 EARNINGS
Q1 2021 CYRAMZA SALES INCREASED 1%

Millions

U.S. sales decreased 10%
International sales increased 7%

Sales by Major Geography

Note: Numbers may not add due to rounding.
Q1 2021 OLUMIANT SALES INCREASED 39%

U.S. sales were $25 million
International sales were $169 million

- Launched in the U.S. in July 2018
- Q1 sales driven by Germany and Japan
- Contributed ~80bps to Q1 WW volume growth

Note: Numbers may not add due to rounding.
Q1 2021 EMGALITY SALES WERE $119 MILLION

Millions

U.S. sales were $101 million
International sales were $18 million

Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 26, 2021; RA = rolling average

2021 Q1 EARNINGS
Q1 2021 TYVYT SALES WERE $110 MILLION

Millions

China sales were $110 million

- Launched in China in Q1 2019
- Part of Lilly collaboration with Innovent
- Contributed ~60bps to Q1 WW volume growth

Note: Numbers may not add due to rounding.
Q1 2021 HUMALOG SALES DECREASED 11%

Millions

U.S. sales decreased 17%
International sales decreased 4%

$696  $617  $555  $657  $718
Q1  Q2  Q3  Q4

U.S. TRx SOM

Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 26, 2021
Q1 2021 BASAGLAR SALES DECREASED 19%

Millions

U.S. sales decreased 24%
International sales decreased 3%

<table>
<thead>
<tr>
<th>Year</th>
<th>U.S. Sales</th>
<th>International Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>$304</td>
<td>$247</td>
</tr>
<tr>
<td>2021</td>
<td>$290</td>
<td>$248</td>
</tr>
</tbody>
</table>

Note: Numbers may not add due to rounding.

U.S. TRx SOM and Market Volume

Source: IQVIA NPA TRx 3MMA, weekly data March 26, 2021; RA = rolling average
Note: Basaglar is part of the Boehringer Ingelheim and Lilly Alliance

Not for promotional use
# SELECT TRIALS – COVID-19 ANTIBODIES

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT04427501</td>
<td>COVID-19</td>
<td>A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness</td>
<td>2/3</td>
<td>3160</td>
<td>Percentage of Participants Who Experience COVID-Related Hospitalization or Death from Any Cause</td>
<td>Sep 2020</td>
<td>Jun 2021</td>
</tr>
<tr>
<td>NCT04497987</td>
<td>COVID-19</td>
<td>A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff</td>
<td>3</td>
<td>5000</td>
<td>Percentage of Participants with COVID-19 within 21 Days of Detection</td>
<td>Jan 2021</td>
<td>Jun 2021</td>
</tr>
<tr>
<td>NCT04656691</td>
<td>COVID-19</td>
<td>At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19</td>
<td>4</td>
<td>4000</td>
<td>Efficacy - determining hospitalization rates</td>
<td>May 2021</td>
<td>May 2021</td>
</tr>
<tr>
<td>NCT04701658</td>
<td>COVID-19</td>
<td>A Real World Study of Bamlanivimab in Participants With Mild-to-moderate Coronavirus Disease 2019 (COVID-19)</td>
<td>2</td>
<td>3000</td>
<td>Percentage of Participants who Experience COVID-19 Related Hospitalization or Death</td>
<td>Jun 2021</td>
<td>Aug 2021</td>
</tr>
<tr>
<td>NCT04634409</td>
<td>COVID-19</td>
<td>A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness</td>
<td>2</td>
<td>700</td>
<td>Percentage of Participants with SARS-CoV-2 Viral Load Greater than 5.27</td>
<td>Aug 2021</td>
<td>Aug 2021</td>
</tr>
<tr>
<td>NCT04501978</td>
<td>COVID-19</td>
<td>ACTIV-3: Therapeutics for Inpatients With COVID-19</td>
<td>3</td>
<td>10000</td>
<td>Time from randomization to sustained recovery</td>
<td>Jul 2022</td>
<td>Jul 2022</td>
</tr>
</tbody>
</table>

1 In collaboration with AbCellera Biologics Inc. and Junshi Bioscience Co., Ltd.
2 In collaboration with NIAID, AbCellera Biologics Inc. and Junshi Bioscience Co., Ltd.
3 Sponsored by United Health Group (UHG), also lists Daniel Griffen and Optum, Inc.
4 In collaboration with AbCellera Biologics Inc.
5 Sponsored by NIAID, also lists INSIGHT, University of Copenhagen, Medical Research Council and more

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 20, 2021
## SELECT TRIALS – COVID-19 ANTIBODIES (CONT.)

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
</table>

⁶ Sponsored by NIAID, and also lists AIDS Clinical Trials Group

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021
## SELECT TRIALS – DONANEMAB

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03367403</td>
<td>Alzheimer Disease</td>
<td>A Study of LY3002813 in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ)</td>
<td>2</td>
<td>266</td>
<td>Change from Baseline in the Integrated Alzheimer’s Disease Rating Scale (iADRS) Score</td>
<td>Dec 2020</td>
<td>Nov 2021</td>
</tr>
<tr>
<td>NCT04640077</td>
<td>Alzheimer Disease</td>
<td>A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer’s Disease (TRAILBLAZER-EXT)</td>
<td>2</td>
<td>100</td>
<td>Part A: Correlation between VTC and on-site assessment for PAIR 1 for Alzheimer’s Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13)</td>
<td>Oct 2022</td>
<td>Mar 2023</td>
</tr>
<tr>
<td>NCT04437511</td>
<td>Alzheimer Disease</td>
<td>A Study of Donanemab (LY3002813) in Participants With Early Alzheimer’s Disease (TRAILBLAZER-ALZ 2)</td>
<td>3</td>
<td>1500</td>
<td>Change from Baseline on the integrated Alzheimer’s Disease Rating Scale (iADRS)</td>
<td>Feb 2023</td>
<td>Dec 2023</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021

Not for promotional use
<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03594110*</td>
<td>Chronic Kidney Disease</td>
<td>EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)</td>
<td>3</td>
<td>6000</td>
<td>Composite primary outcome: Time to first occurrence of (i) kidney disease progression [defined as ESKD, a sustained decline in eGFR to &lt;10 mL/min/1.73m², renal death, or a sustained decline of ≥40% in eGFR from randomization] or (ii) Cardiovascular death</td>
<td>Oct 2022</td>
<td>Oct 2022</td>
</tr>
<tr>
<td>NCT03057951</td>
<td>Heart Failure</td>
<td>EMPagliflozin outcomeTRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction [EMPEROR-Preserved]</td>
<td>3</td>
<td>5988</td>
<td>Composite primary endpoint - Time to first event of adjudicated CV (Cardiovascular) death or adjudicated HHF (Hospitalisation for Heart Failure) in patients with Heart Failure with preserved Ejection Fraction (HFpEF)</td>
<td>Apr 2021</td>
<td>Apr 2021</td>
</tr>
<tr>
<td>NCT04157751</td>
<td>Heart Failure</td>
<td>A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure</td>
<td>3</td>
<td>500</td>
<td>The clinical benefit, a composite of death, number of HFE [including HHFs], urgent heart failure visits and unplanned outpatient visits, time to first HFE and change from baseline KCCQ-TSS after 90 days of treatment assessed by the win ratio.</td>
<td>May 2021</td>
<td>Jun 2021</td>
</tr>
<tr>
<td>NCT04509674</td>
<td>Myocardial Infarction</td>
<td>EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)</td>
<td>3</td>
<td>3312</td>
<td>Composite of time to first heart failure hospitalisation or all-cause mortality</td>
<td>Dec 2022</td>
<td>Dec 2022</td>
</tr>
</tbody>
</table>

In collaboration with Boehringer Ingelheim

*Also lists Medical Research Council Population Health Research Unit, CTSU, University of Oxford [academic lead]

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 13, 2021
## SELECT TRIALS – LEBRIKIZUMAB

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT04178967</td>
<td>Atopic Dermatitis</td>
<td>Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADVocate1)</td>
<td>3</td>
<td>400</td>
<td>Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16</td>
<td>Jun 2021</td>
<td>Jun 2022</td>
</tr>
<tr>
<td>NCT04146363</td>
<td>Atopic Dermatitis</td>
<td>Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADVocate1)</td>
<td>3</td>
<td>424</td>
<td>Percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16</td>
<td>Jun 2021</td>
<td>May 2022</td>
</tr>
<tr>
<td>NCT04250337</td>
<td>Atopic Dermatitis</td>
<td>Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.</td>
<td>3</td>
<td>225</td>
<td>The primary efficacy endpoint is the percentage of participants with an IGA score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16.</td>
<td>Aug 2021</td>
<td>Oct 2021</td>
</tr>
<tr>
<td>NCT04626297</td>
<td>Atopic Dermatitis</td>
<td>A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADOpt-VA)</td>
<td>3</td>
<td>240</td>
<td>Percentage of Participants who Develop a Booster Response to Tetanus Toxoid 4 Weeks after Vaccine Administration</td>
<td>Nov 2021</td>
<td>Jan 2022</td>
</tr>
<tr>
<td>NCT04250350</td>
<td>Atopic Dermatitis</td>
<td>Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis (ADopt-VA)</td>
<td>3</td>
<td>200</td>
<td>Percentage of Participants Discontinued from Study Treatment Due to Adverse Events</td>
<td>Apr 2022</td>
<td>Jul 2022</td>
</tr>
<tr>
<td>NCT04760314</td>
<td>Atopic Dermatitis</td>
<td>A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis</td>
<td>3</td>
<td>280</td>
<td>Percentage of Participants with an Investigators Global Assessment (IGA) score of 0 or 1 and a reduction ≥2 points from Baseline to Week 16</td>
<td>Oct 2022</td>
<td>May 2023</td>
</tr>
<tr>
<td>NCT04392154</td>
<td>Atopic Dermatitis</td>
<td>Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)</td>
<td>3</td>
<td>1000</td>
<td>Percentage of Participants Discontinued from Study Treatment due to Adverse Events through the Last Treatment Visit</td>
<td>May 2024</td>
<td>May 2024</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021
<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03740919</td>
<td>Type 1 Diabetes Mellitus</td>
<td>A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes</td>
<td>3</td>
<td>945</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c) (Prandial Dosing)</td>
<td>Jul 2021</td>
<td>Jul 2021</td>
</tr>
<tr>
<td>NCT03952130</td>
<td>Type 1 Diabetes Mellitus</td>
<td>A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes</td>
<td>3</td>
<td>350</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c)</td>
<td>Dec 2021</td>
<td>Dec 2021</td>
</tr>
<tr>
<td>NCT04605991</td>
<td>Type 2 Diabetes</td>
<td>A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)</td>
<td>3</td>
<td>167</td>
<td>Change from Baseline in Percentage of Time with CGM Glucose Values between 70-180 milligrams/deciliter (mg/dL) (3.9-10.0 millimoles/Liter [mmol/L]) (both inclusive) during Daytime Period with 14 Days of CGM Use</td>
<td>Sep 2021</td>
<td>Sep 2021</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021

Not for promotional use
<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03556202</td>
<td>Psoriasis</td>
<td>A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)</td>
<td>3</td>
<td>1816</td>
<td>Percentage of Participants with a Static Physician’s Global Assessment Among Those who Entered the Study with a sPGA of 0,1sPGA of [0,1]</td>
<td>May 2024</td>
<td>May 2024</td>
</tr>
<tr>
<td>NCT03926130</td>
<td>Crohn's Disease</td>
<td>A Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease</td>
<td>3</td>
<td>1150</td>
<td>Percentage of Participants Achieving Endoscopic Response</td>
<td>Dec 2022</td>
<td>Apr 2023</td>
</tr>
<tr>
<td>NCT04232553</td>
<td>Crohn's Disease</td>
<td>A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease</td>
<td>3</td>
<td>778</td>
<td>Percentage of Participants Achieving Endoscopic Response</td>
<td>Jun 2024</td>
<td>Jun 2024</td>
</tr>
<tr>
<td>NCT03518086</td>
<td>Ulcerative Colitis</td>
<td>An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)</td>
<td>3</td>
<td>1160</td>
<td>Percentage of Participants in Clinical Remission</td>
<td>Dec 2021</td>
<td>Nov 2022</td>
</tr>
<tr>
<td>NCT03524092</td>
<td>Ulcerative Colitis</td>
<td>A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis</td>
<td>3</td>
<td>1044</td>
<td>Percentage of Participants in Clinical Remission</td>
<td>Jun 2023</td>
<td>Aug 2023</td>
</tr>
<tr>
<td>NCT03519945</td>
<td>Ulcerative Colitis</td>
<td>A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)</td>
<td>3</td>
<td>960</td>
<td>Percentage of Participants in Clinical Remission</td>
<td>Aug 2023</td>
<td>Jul 2025</td>
</tr>
<tr>
<td>NCT0449062</td>
<td>Ulcerative Colitis</td>
<td>A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis</td>
<td>3</td>
<td>1100</td>
<td>Percentage of Participants in Histologic Remission</td>
<td>Mar 2024</td>
<td>Jun 2024</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021
<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT04844606</td>
<td>Ulcerative Colitis</td>
<td>A Master Protocol (AMA2): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn’s Disease (SHINE-ON)</td>
<td>3</td>
<td>185</td>
<td>Percentage of Participants in Modified Mayo Score (MMS) Clinical Remission</td>
<td>Sep 2027</td>
<td>Sep 2027</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021
# SELECT TRIALS – OLUMIANT

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03899259</td>
<td>Alopecia Areata</td>
<td>A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata</td>
<td>3</td>
<td>476</td>
<td>Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20</td>
<td>Jan 2021</td>
<td>May 2024</td>
</tr>
<tr>
<td>NCT03570749</td>
<td>Alopecia Areata</td>
<td>A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata</td>
<td>2</td>
<td>3</td>
<td>725</td>
<td>Percentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20</td>
<td>Feb 2021</td>
</tr>
<tr>
<td>NCT04421027</td>
<td>COVID-19</td>
<td>A Study of Baricitinib (LY3009104) in Participants With COVID-19</td>
<td>3</td>
<td>1400</td>
<td>Percentage of Participants who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation [including extracorporeal membrane oxygenation (ECMO)]</td>
<td>May 2021</td>
<td>Jun 2021</td>
</tr>
</tbody>
</table>

In collaboration with Incyte

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021

Not for promotional use
# SELECT TRIALS – PIRTOBRUTINIB

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT04849416</td>
<td>Leukemia, Lymphoid</td>
<td>A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)</td>
<td>2</td>
<td>126</td>
<td>Overall Response Rate (ORR)</td>
<td>Aug 2022</td>
<td>Apr 2025</td>
</tr>
<tr>
<td>NCT03740529</td>
<td>Chronic Lymphocytic Leukemia</td>
<td>A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL</td>
<td>1/2</td>
<td>860</td>
<td>Maximum Tolerated Dose (MTD)</td>
<td>Feb 2023</td>
<td>May 2023</td>
</tr>
<tr>
<td>NCT04666038</td>
<td>Chronic Lymphocytic Leukemia</td>
<td>Study of LOXO-305 Versus Investigator’s Choice (IdelaR or BR) in Patients With CLL or SLL</td>
<td>3</td>
<td>250</td>
<td>To evaluate progression-free survival (PFS) of LOXO-305 monotherapy (Arm A) compared to investigator’s choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) (Arm B)</td>
<td>Jan 2024</td>
<td>Jun 2024</td>
</tr>
<tr>
<td>NCT04662255</td>
<td>Lymphoma Mantle-Cell</td>
<td>Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)</td>
<td>3</td>
<td>500</td>
<td>To compare progression-free survival (PFS) of LOXO-305 as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)</td>
<td>Aug 2024</td>
<td>Feb 2025</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021
# SELECT TRIALS – RETEVMO

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03899792</td>
<td>Medullary Thyroid Cancer</td>
<td>A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors</td>
<td>1/2</td>
<td>100</td>
<td>To Determine the Safety of Oral LOXO-292 in Pediatric Participants with Advanced Solid Tumors: Dose Limiting Toxicities (DLTs)</td>
<td>Mar 2023</td>
<td>Mar 2024</td>
</tr>
<tr>
<td>NCT04211337</td>
<td>Medullary Thyroid Cancer</td>
<td>A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer</td>
<td>3</td>
<td>400</td>
<td>Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)</td>
<td>May 2024</td>
<td>Nov 2026</td>
</tr>
<tr>
<td>NCT03157128</td>
<td>Non-Small Cell Lung Cancer</td>
<td>Phase 1/2 Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer</td>
<td>1/2</td>
<td>989</td>
<td>Phase 1: MTD</td>
<td>Nov 2022</td>
<td>Nov 2023</td>
</tr>
<tr>
<td>NCT04194944</td>
<td>Non-Small Cell Lung Cancer</td>
<td>A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer</td>
<td>3</td>
<td>250</td>
<td>Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with Pembrolizumab)</td>
<td>Jan 2023</td>
<td>Aug 2025</td>
</tr>
<tr>
<td>NCT04819100</td>
<td>Non-Small Cell Lung Cancer</td>
<td>A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)</td>
<td>3</td>
<td>170</td>
<td>Event-Free Survival (EFS)</td>
<td>Aug 2028</td>
<td>Nov 2032</td>
</tr>
<tr>
<td>NCT04280081</td>
<td>Solid Tumor</td>
<td>A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation</td>
<td>2</td>
<td>75</td>
<td>Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR) by Independent Review Committee</td>
<td>Mar 2021</td>
<td>Apr 2023</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 20, 2021

Not for promotional use
## SELECT TRIALS – SOLANEZUMAB

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome*</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02008357*</td>
<td>Cognition Disorders</td>
<td>Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss</td>
<td>3</td>
<td>1150</td>
<td>Change from Baseline of the Preclinical Alzheimer Cognitive Composite (PACC)</td>
<td>Dec 2022</td>
<td>Dec 2022</td>
</tr>
</tbody>
</table>

* Also lists Alzheimer’s Therapeutic Research Institute

* Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 26, 2021

Not for promotional use
## SELECT TRIALS – TANEZUMAB

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02609828</td>
<td>Neoplasm Metastasis</td>
<td>Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.</td>
<td>3</td>
<td>156</td>
<td>Change from baseline in daily average pain intensity in index bone metastasis cancer pain site</td>
<td>Sep 2020</td>
<td>Jul 2021</td>
</tr>
</tbody>
</table>

In collaboration with Pfizer

*Molecule may have multiple indications; Indication is for pain associated with the condition listed

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, March 23, 2020
<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT04166773</td>
<td>Nonalcoholic Steatohepatitis</td>
<td>A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)</td>
<td>2</td>
<td>196</td>
<td>Percentage of Participants with Absence of NASH with no Worsening of Fibrosis on Liver Histology</td>
<td>Jun 2022</td>
<td>Jun 2022</td>
</tr>
<tr>
<td>NCT04184622</td>
<td>Obesity</td>
<td>A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight</td>
<td>3</td>
<td>2400</td>
<td>Percent Change from Baseline in Body Weight</td>
<td>Apr 2022</td>
<td>May 2024</td>
</tr>
<tr>
<td>NCT04657003</td>
<td>Obesity</td>
<td>A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight</td>
<td>3</td>
<td>900</td>
<td>Percent Change from Randomization in Body Weight</td>
<td>Jun 2023</td>
<td>Jul 2023</td>
</tr>
<tr>
<td>NCT04844918</td>
<td>Obesity</td>
<td>A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease</td>
<td>3</td>
<td>261</td>
<td>Percentage of Participants who Achieve ≥5% Body Weight Reduction</td>
<td>Jul 2023</td>
<td>Jul 2023</td>
</tr>
<tr>
<td>NCT04660643</td>
<td>Obesity</td>
<td>A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss</td>
<td>3</td>
<td>750</td>
<td>Percent Change from Randomization (Week 36) in Body Weight</td>
<td>Aug 2023</td>
<td>Aug 2023</td>
</tr>
<tr>
<td>NCT04657016</td>
<td>Obesity</td>
<td>A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program</td>
<td>3</td>
<td>800</td>
<td>Percent Change from Randomization in Body Weight</td>
<td>Aug 2023</td>
<td>Sep 2023</td>
</tr>
<tr>
<td>NCT04847557</td>
<td>Obesity</td>
<td>A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)</td>
<td>3</td>
<td>700</td>
<td>A Hierarchical Composite of All-Cause Mortality, Heart Failure Events, 6-minute Walk Test Distance (6MWD) and Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) Category</td>
<td>Nov 2023</td>
<td>Nov 2023</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021
<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03730662</td>
<td>Type 2 Diabetes Mellitus</td>
<td>A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk</td>
<td>3</td>
<td>1878</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c) [10 mg and 15 mg]</td>
<td>Mar 2021</td>
<td>Jun 2021</td>
</tr>
<tr>
<td>NCT04093752</td>
<td>Type 2 Diabetes</td>
<td>A Study of Tirzepatide [LY3298176] in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)</td>
<td>3</td>
<td>917</td>
<td>Mean Change from Baseline in Hemoglobin A1c (HbA1c) [10 mg and 15 mg]</td>
<td>Oct 2021</td>
<td>Nov 2021</td>
</tr>
<tr>
<td>NCT04537923</td>
<td>Type 2 Diabetes</td>
<td>A Study of Tirzepatide [LY3298176] Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin</td>
<td>3</td>
<td>1182</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c) [Pooled Doses]</td>
<td>Aug 2022</td>
<td>Sep 2022</td>
</tr>
<tr>
<td>NCT04255433</td>
<td>Type 2 Diabetes Mellitus</td>
<td>A Study of Tirzepatide [LY3298176] Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes</td>
<td>3</td>
<td>12500</td>
<td>Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke [MACE-3]</td>
<td>Oct 2024</td>
<td>Oct 2024</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021
<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03155997*</td>
<td>Breast Cancer</td>
<td>Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer</td>
<td>3</td>
<td>5637</td>
<td>Invasive Disease Free Survival (IDFS)</td>
<td>Mar 2020</td>
<td>Jun 2029</td>
</tr>
</tbody>
</table>

* Also lists NSABP Foundation Inc

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, November 20, 2020
## SELECT TRIALS – EARLY PHASE DIABETES

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal Insulin - FC</td>
<td>NCT04450407</td>
<td>Type 1 Diabetes Mellitus</td>
<td>A Study of LY3209590 in Participants With Type 1 Diabetes</td>
<td>2</td>
<td>254</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c)</td>
<td>Sep 2021</td>
<td>Sep 2021</td>
</tr>
<tr>
<td>Basal Insulin - FC</td>
<td>NCT04450394</td>
<td>Type 2 Diabetes Mellitus</td>
<td>A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus</td>
<td>2</td>
<td>264</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c)</td>
<td>Sep 2021</td>
<td>Sep 2021</td>
</tr>
<tr>
<td>GLP-1R NPA</td>
<td>NCT04680767</td>
<td>Healthy</td>
<td>A Study of LY3502970 in Healthy Male Participants</td>
<td>1</td>
<td>8</td>
<td>Fecal Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</td>
<td>May 2021</td>
<td>May 2021</td>
</tr>
<tr>
<td>GLP-1R NPA</td>
<td>NCT04426474</td>
<td>Diabetes Mellitus, Type 2</td>
<td>A Study of LY3502970 in Participants With Type 2 Diabetes</td>
<td>1</td>
<td>60</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</td>
<td>Jun 2021</td>
<td>Jun 2021</td>
</tr>
<tr>
<td>KHK Inhibitor</td>
<td>NCT04270370</td>
<td>Healthy</td>
<td>A Study of LY3478045 in Healthy Participants</td>
<td>1</td>
<td>90</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Jun 2021</td>
<td>Jun 2021</td>
</tr>
<tr>
<td>GIP/GLP-1 Coagonist II</td>
<td>NCT04648865</td>
<td>Healthy</td>
<td>A Study of LY3537031 in Healthy Participants</td>
<td>1</td>
<td>60</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Jun 2021</td>
<td>Jun 2021</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021
<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxyntomodulin</td>
<td>NCT03928379</td>
<td>Diabetes Mellitus, Type 2</td>
<td>A Study of LY3305677 in Participants With Type 2 Diabetes</td>
<td>1</td>
<td>36</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug</td>
<td>Jul 2021</td>
<td>Jul 2021</td>
</tr>
<tr>
<td>GIP/GLP Coagonist Peptide</td>
<td>NCT04682106</td>
<td>Healthy</td>
<td>A Study of LY3493269 in Healthy Participants</td>
<td>1</td>
<td>56</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Sep 2021</td>
<td>Sep 2021</td>
</tr>
<tr>
<td>Basal Insulin - FC</td>
<td>NCT04768842</td>
<td>Healthy</td>
<td>A Study of Two Different Formulations of LY3209590 in Healthy Participants</td>
<td>1</td>
<td>50</td>
<td>Pharmacokinetics [PK]: Maximum Concentration [Cmax] of LY3209590</td>
<td>Sep 2021</td>
<td>Sep 2021</td>
</tr>
<tr>
<td>KHK Inhibitor II</td>
<td>NCT04559568</td>
<td>Healthy</td>
<td>A Study of LY3522348 in Healthy Participants</td>
<td>1</td>
<td>100</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Sep 2021</td>
<td>Sep 2021</td>
</tr>
<tr>
<td>PYY Analog Agonist</td>
<td>NCT04641312</td>
<td>Healthy</td>
<td>A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes</td>
<td>1</td>
<td>90</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Sep 2021</td>
<td>Sep 2021</td>
</tr>
<tr>
<td>LP(a) Inhibitor</td>
<td>NCT04472676</td>
<td>Healthy</td>
<td>A Study of LY3473329 in Healthy Participants</td>
<td>1</td>
<td>107</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Oct 2021</td>
<td>Oct 2021</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 23, 2021
<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>GIPR Agonist LA</td>
<td>NCT04586907</td>
<td>Healthy</td>
<td>A Study of LY3537021 in Healthy Participants</td>
<td>1</td>
<td>50</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Nov 2021</td>
<td>Nov 2021</td>
</tr>
<tr>
<td>GGG Tri-Agonist</td>
<td>NCT04823208</td>
<td>Diabetes Mellitus, Type 2</td>
<td>A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)</td>
<td>1</td>
<td>66</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Jan 2022</td>
<td>Jan 2022</td>
</tr>
<tr>
<td>Relaxin-LA</td>
<td>NCT04768855</td>
<td>Healthy</td>
<td>A Study of LY3540378 in Healthy Participants</td>
<td>1</td>
<td>120</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Mar 2022</td>
<td>Mar 2022</td>
</tr>
<tr>
<td>ANGPTL3-siRNA</td>
<td>NCT04644809</td>
<td>Dyslipidemias</td>
<td>A Study of LY3561774 in Participants With Dyslipidemia</td>
<td>1</td>
<td>74</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Apr 2022</td>
<td>Apr 2022</td>
</tr>
<tr>
<td>NRG4 Agonist I</td>
<td>NCT04840914</td>
<td>Chronic Heart Failure With Reduced Ejection Fraction</td>
<td>A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction</td>
<td>1</td>
<td>50</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Feb 2023</td>
<td>Feb 2023</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021
## SELECT TRIALS – EARLY PHASE IMMUNOLOGY

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD200R MAB</td>
<td>NCT04159701</td>
<td>Chronic Spontaneous Urticaria</td>
<td>A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria</td>
<td>2</td>
<td>60</td>
<td>Mean Change from Baseline in Urticaria Activity Score Over 7 Days (UA57)</td>
<td>Mar 2021</td>
<td>Sep 2021</td>
</tr>
<tr>
<td>Agonist</td>
<td>NCT04493502</td>
<td>Hidradenitis Suppurativa</td>
<td>A Study of LY3041658 in Adults With Hidradenitis Suppurativa</td>
<td>2</td>
<td>52</td>
<td>Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR)</td>
<td>Dec 2021</td>
<td>Jul 2022</td>
</tr>
<tr>
<td>PD-1 Mab</td>
<td>NCT04634253</td>
<td>Rheumatoid Arthritis</td>
<td>A Study of LY3462817 in Participants With Rheumatoid Arthritis</td>
<td>2</td>
<td>80</td>
<td>Change from Baseline on the Disease Activity Score Modified to Include the 28 Diarthrodial Joint Count- High-Sensitivity C-Reactive Protein [DAS28-hsCRP]</td>
<td>Feb 2022</td>
<td>Aug 2022</td>
</tr>
<tr>
<td>IL-2 CONJUGATE</td>
<td>NCT04677179</td>
<td>Colitis, Ulcerative</td>
<td>A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis [UC]</td>
<td>2</td>
<td>200</td>
<td>Percentage of Participants in Clinical Remission</td>
<td>Jul 2023</td>
<td>Jul 2024</td>
</tr>
<tr>
<td>IL-2 CONJUGATE</td>
<td>NCT03933943</td>
<td>Lupus Erythematosus, Systemic</td>
<td>A Study of LY3361237 in Participants With Systemic Lupus Erythematosus</td>
<td>1</td>
<td>28</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</td>
<td>Feb 2021</td>
<td>Feb 2021</td>
</tr>
</tbody>
</table>

^ Also lists Nektar Therapeutics  
*Molecule may have multiple indications  
**Trial may have additional primary and other secondary outcomes  
Source: clinicaltrials.gov, April 19, 2021
## SELECT TRIALS – EARLY PHASE IMMUNOLOGY (CONT.)

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>CXCR1/2L mAb</td>
<td>NCT04653168</td>
<td>Healthy</td>
<td>A Study of LY3041658 in Healthy Participants</td>
<td>1</td>
<td>16</td>
<td>Number of Participants With incidence and severity of Injection Site Reaction (ISR)</td>
<td>May 2021</td>
<td>May 2021</td>
</tr>
<tr>
<td>CD200R MAB Agonist</td>
<td>NCT03750643</td>
<td>Dermatitis, Atopic</td>
<td>A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis</td>
<td>1</td>
<td>64</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Jun 2021</td>
<td>Aug 2021</td>
</tr>
<tr>
<td>IL-17A Small Molecule Inhibitor</td>
<td>NCT04586920</td>
<td>Healthy</td>
<td>A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants</td>
<td>1</td>
<td>121</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Aug 2021</td>
<td>Aug 2021</td>
</tr>
<tr>
<td>PD-1 Mab Agonist</td>
<td>NCT04152382</td>
<td>Psoriasis</td>
<td>A Safety Study of LY3462817 in Participants With Psoriasis</td>
<td>1</td>
<td>64</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Oct 2021</td>
<td>Oct 2021</td>
</tr>
<tr>
<td>IL-2 CONJUGATE</td>
<td>NCT04119557</td>
<td>Psoriasis</td>
<td>A Study of LY3471851 in Participants With Psoriasis</td>
<td>1</td>
<td>40</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Dec 2021</td>
<td>Dec 2021</td>
</tr>
<tr>
<td>IL-2 CONJUGATE</td>
<td>NCT04081350</td>
<td>Dermatitis, Atopic</td>
<td>A Study of LY3471851 in Participants With Eczema</td>
<td>1</td>
<td>40</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Sep 2022</td>
<td>Sep 2022</td>
</tr>
</tbody>
</table>

^ Also lists Nektar Therapeutics  
*Molecule may have multiple indications  
**Trial may have additional primary and other secondary outcomes  

Source: clinicaltrials.gov, April 19, 2021
<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>O-GlcNAcase Inh.</td>
<td>NCT04392271</td>
<td>Healthy</td>
<td>A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants</td>
<td>1</td>
<td>4</td>
<td>Percent O-GlcNAcase (OGA) Enzyme Occupancy (EO)</td>
<td>Oct 2020</td>
<td>Oct 2020</td>
</tr>
<tr>
<td>Mevidalen (D1 PAM)</td>
<td>NCT04258826</td>
<td>Healthy</td>
<td>A Study to Evaluate LY3154207 on the Brain of Healthy Participants</td>
<td>1</td>
<td>34</td>
<td>Change from Baseline in Intrinsic Functional Connectivity Among Resting-State Networks of the Brain</td>
<td>Nov 2021</td>
<td>Nov 2021</td>
</tr>
<tr>
<td>N3PG A8 MAB</td>
<td>NCT04451408</td>
<td>Alzheimer Disease</td>
<td>A Study of LY3372993 in Participants With Alzheimer’s Disease [AD]</td>
<td>1</td>
<td>30</td>
<td>Number of Participants with One or More Serious Adverse Event(s) [SAEs] Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Apr 2022</td>
<td>Apr 2022</td>
</tr>
<tr>
<td>GBA1 Gene Therapy</td>
<td>NCT04127578</td>
<td>Parkinson Disease</td>
<td>Phase 1/2a Clinical Trial of PR001A in Patients With Parkinson’s Disease With at Least One GBA1 Mutation (PROPEL)</td>
<td>1</td>
<td>2</td>
<td>12</td>
<td>Number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</td>
<td>Jun 2027</td>
</tr>
<tr>
<td>GRN Gene Therapy</td>
<td>NCT04408625</td>
<td>Frontotemporal Dementia</td>
<td>Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)</td>
<td>1</td>
<td>2</td>
<td>15</td>
<td>Number of Adverse Events [AEs], Serious Adverse Events [SAEs], and Adverse Events Leading to discontinuation</td>
<td>Dec 2027</td>
</tr>
<tr>
<td>GBA1 Gene Therapy</td>
<td>NCT04411654</td>
<td>Gaucher Disease, Type 2</td>
<td>Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease [PROVIDE]</td>
<td>1</td>
<td>2</td>
<td>15</td>
<td>Number of Adverse Events [AEs], Serious Adverse Events [SAEs], and Adverse Events leading to discontinuation</td>
<td>Apr 2028</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021
## SELECT TRIALS – EARLY PHASE ONCOLOGY

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>SERD</td>
<td>NCT04840888</td>
<td>Healthy</td>
<td>A Study of LY3484356 in Healthy Female Participants</td>
<td>1</td>
<td>60</td>
<td>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356</td>
<td>Jul 2021</td>
<td>Jul 2021</td>
</tr>
<tr>
<td>SERD</td>
<td>NCT04188548</td>
<td>Breast Cancer</td>
<td>A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer</td>
<td>1</td>
<td>460</td>
<td>Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities</td>
<td>Jul 2021</td>
<td>Apr 2023</td>
</tr>
<tr>
<td>SERD</td>
<td>NCT04647487</td>
<td>Breast Cancer</td>
<td>A Study of LY3484356 in Women With Breast Cancer Before Having Surgery</td>
<td>1</td>
<td>60</td>
<td>Change from Baseline in ER Expression</td>
<td>Mar 2022</td>
<td>Mar 2022</td>
</tr>
<tr>
<td>IDH1 Inhibitor</td>
<td>NCT04603001</td>
<td>Acute Myeloid Leukemia (AML)</td>
<td>Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations</td>
<td>1</td>
<td>220</td>
<td>To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)</td>
<td>Feb 2023</td>
<td>Sep 2023</td>
</tr>
<tr>
<td>IDH1 Inhibitor</td>
<td>NCT04521686</td>
<td>Cholangiocarcinoma</td>
<td>Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations</td>
<td>1</td>
<td>180</td>
<td>Recommended Phase 2 dose (RP2D)</td>
<td>Feb 2023</td>
<td>Sep 2023</td>
</tr>
<tr>
<td>Aur A Kinase Inhibitor</td>
<td>NCT04106219</td>
<td>Neuroblastoma</td>
<td>A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma</td>
<td>1</td>
<td>71</td>
<td>Number of Participants with Dose Limiting Toxicities (DLTs)</td>
<td>Apr 2024</td>
<td>Apr 2025</td>
</tr>
</tbody>
</table>

^ Also lists New Approaches to Neuroblastoma Therapy Consortium (NANT) and Innovative Therapies for Children with Cancer in Europe (ITCC)

* Molecule may have multiple indications

** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 19, 2021
# SELECT TRIALS – EARLY PHASE PAIN

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPIREG/TGFα MAB</td>
<td>NCT04456686</td>
<td>Osteoarthritis</td>
<td>Chronic Pain Master Protocol [CPMP]: A Study of LY3016859 in Participants With Osteoarthritis</td>
<td>2</td>
<td>125</td>
<td>Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)</td>
<td>Apr 2021</td>
<td>Sep 2022</td>
</tr>
<tr>
<td>EPIREG/TGFα MAB</td>
<td>NCT04529096</td>
<td>Chronic Low-back Pain</td>
<td>Chronic Pain Master Protocol [CPMP]: A Study of LY3016859 in Participants With Chronic Low Back Pain</td>
<td>2</td>
<td>150</td>
<td>Change from Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)</td>
<td>Jun 2021</td>
<td>Nov 2022</td>
</tr>
<tr>
<td>EPIREG/TGFα MAB</td>
<td>NCT04476108</td>
<td>Diabetic Peripheral Neuropathic Pain</td>
<td>Chronic Pain Master Protocol [CPMP]: A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain</td>
<td>2</td>
<td>125</td>
<td>Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)</td>
<td>Aug 2021</td>
<td>Jan 2023</td>
</tr>
<tr>
<td>PACAP38 MAB</td>
<td>NCT04498910</td>
<td>Migraine</td>
<td>A Study of LY3451838 in Participants With Migraine</td>
<td>2</td>
<td>120</td>
<td>Change from Baseline in the Number of Monthly Migraine Headache Days</td>
<td>Nov 2021</td>
<td>Nov 2021</td>
</tr>
<tr>
<td>SSTR4 Agonist</td>
<td>NCT04627038</td>
<td>Osteoarthritis</td>
<td>Chronic Pain Master Protocol [CPMP]: A Study of LY3556050 in Participants With Osteoarthritis</td>
<td>2</td>
<td>200</td>
<td>Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)</td>
<td>Dec 2021</td>
<td>Dec 2021</td>
</tr>
<tr>
<td>SSTR4 Agonist</td>
<td>NCT04707157</td>
<td>Diabetic Peripheral Neuropathic Pain</td>
<td>Chronic Pain Master Protocol [CPMP]: A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain</td>
<td>2</td>
<td>200</td>
<td>Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)</td>
<td>Apr 2022</td>
<td>Apr 2022</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications  
**Trial may have additional primary and other secondary outcomes

Source: [clinicaltrials.gov](http://clinicaltrials.gov), April 19, 2021
## SELECT TRIALS – EARLY PHASE PAIN (CONT.)

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRPA1 Antagonist I</td>
<td>NCT04682119</td>
<td>Healthy</td>
<td>A Safety Study of LY3526318 in Healthy Participants</td>
<td>1</td>
<td>16</td>
<td>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3526318</td>
<td>Apr 2021</td>
<td>Apr 2021</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications  
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 22, 2021